34 results about "Brinzolamide" patented technology

A sterile aqueous formulation of a carbonic anhydrase inhibitor such as brinzolamide in combination with polymers like Soluplus® and a surfactant like polysorbate 80, as well as methods of preparation thereof, is disclosed. The formulation relates to the highly solubilized or an amorphous form of poorly insoluble drugs/active ingredient(s) to improve its bio-availability and manufacturability.

The invention relates to the field of medicines and in particular relates to a brinzolamide nanosuspension preparation used for eyes as well as a preparation method and application thereof, aiming to lengthen the residence time of the preparation on the eyes or improve the bioavailability of the preparation. The preparation can be used for treating the diseases, such as intraocular hypertension and glaucoma. Gels can conduce to lengthening the retention time of the medicine on the eyes and reducing the number of times of administration and the dosage of administration, so that not only is the patient compliance improved but also the side effects of the medicine can be reduced. Meanwhile, no preservative is added and single-dosage package is adopted, thus reducing the irritation of eye drops used for a long term to the eyes and greatly improving the medication safety.

The invention relates to the field of medicines and in particular relates to a brinzolamide nanoparticle preparation used for eyes as well as a preparation method and application thereof, aiming to lengthen the residence time of the preparation on the eyes or improve the bioavailability of the preparation. The preparation can be used for treating the diseases, such as intraocular hypertension and glaucoma. Gels can conduce to lengthening the retention time of the medicine on the eyes and reducing the number of times of administration and the dosage of administration, so that not only is the patient compliance improved but also the side effects of the medicine can be reduced. Meanwhile, no preservative is added and single-dosage package is adopted, thus reducing the irritation of eye drops used for a long term to the eyes and greatly improving the medication safety.

The invention belongs to the technical field of drugs, and particularly relates to a brinzolamide brimonidine eye drop and a preparation method thereof. The brinzolamide brimonidine eye drop is prepared from, by weight, 1-3% of brinzolamide, 1-5% of brimonidine, 0.3-0.8% of osmotic pressure conditioning agent, 0.1-1% of glycosaminoglycan, pH conditioning agent and balance water for injection, wherein the addition amount of the pH conditioning agent enables pH of the eye drop to be 5.5-7.5. The prepared eye drop containing the brinzolamide brimonidine and iso-osmia with tears have the advantages of not containing preservative, being capable of effectively reducing intraocular pressure and having no secondary damage to eyes caused by the preservative.

The invention belongs to the technical field of pharmaceutical chemicals, in particular relates to a method for preparing an intermediate thiophene sulfonamide of brinzolamide and is applicable to industrial production. The method comprises the following steps: dissolving thiophene benzyl sulfide in a proper solvent, adding glacial acetic acid and water, controlling the temperature to 0-15 DEG C, adding trichloroisocyanuric acid in batches in 20-40 minutes, reacting at the constant temperature until the raw materials disappear, performing vacuum concentration in a water bath at the temperature of 30-50 DEG C to remove the solvent, adding ethyl acetate petroleum ether solution with the mass concentration of ethyl acetate being 25%, stirring, filtering, evaporating the filtrate under reduced pressure, thereby obtaining thiophenesulfonyl chloride; controlling the temperature to 0-15 DEG C, diluting thiophenesulfonyl chloride by ethyl acetate, dropwise adding a dilution into ammonium hydroxide or a water solution of amine, stirring and reacting until the raw materials disappear, filtering, washing, drying the solids, and obtaining the thiophene sulfonamide. The product obtained by using the method is high in yield, simple and convenient in operation, low in cost and mild in reaction conditions and is suitable for large-scale production.

The invention relates to a preparation method of a brinzolamide intermediate I and an intermediate compound III. The preparation method is simple to operate, mild in reaction condition, high in efficiency and low in cost, and is suitable for industrial production.

The invention discloses a preparation method of a molecularly imprinted hydrogel contact lens for sustained and controlled release administration. The method comprises the following steps: mixing choline chloride and methacrylic acid according to a certain proportion, and preparing a hydrophilic functional monomer deep eutectic solvent (DES) in an oil bath at 90 DEG C; taking brinzolamide as a template, hydroxyethyl methacrylate as a framework monomer, DES as a functional monomer, and polyethylene glycol dimethacrylate as a crosslinking agent to perform ultrasonic treatment under action of aninitiator AIBN to obtain a pre-polymerization solution; removing oxygen from the pre-polymerization solution, performing balancing in the dark, then injecting the pre-polymerization solution into a mold, performing ultraviolet polymerization, performing cutting by a round punch, performing eluting to remove unreacted substances, and performing drying to obtain the hydrogel contact lens. The hydrogel contact lens prepared by the preparation method has large drug loading amount, can realize slow release of drugs, and has the advantages of greatly improved bioavailability, good permeability, longretention time, better convenience and higher efficiency compared with a traditional ophthalmic preparation.

The present invention relates to the field of drug delivery and, particularly, to alternative processes for preparing ophthalmic compositions of Brinzolamide or pharmaceutical acceptable salts thereof.

The invention discloses preparation methods of brinzolamide and an intermediate thereof. The preparation method of the brinzolamide intermediate represented by a compound C comprises: carrying out a condensation reaction on a compound B and an orthoester-based compound at a temperature of 70-80 DEG C in an organic solvent in the presence of tertiary amine under an anhydrous condition, wherein theorthoester-based compound is one or a plurality of materials selected from trimethyl orthoacetate, triethyl orthoacetate and trimethyl orthobenzoate. According to the present invention, the condensation reaction is performed by using the tertiary amine as the catalyst, such that the reaction time for the amino protection is substantially shortened, the consumption of the protection reagent is reduced, the reaction temperature is reduced, the yield and the purity of the product are improved, the acid consumption and the alkali consumption during the post-treatment are reduced, the residue on ignition of the product is reduced, the operation is simplified, and the method is suitable for industrial production. The formulas B and C are defined in the specification.

The present invention relates to the use of pyrimidylaminobenzamide derivatives for the preparation of a drug for the treatment of non-cancerous, benign brain tumors, especially for the curative and/or prophylactic treatment of NF, and to a method of treating non-cancerous, benign brain tumors, especially for the curative and/or prophylactic treatment of NF.

The invention discloses a high-efficiency herbal eye drop, and belongs to the field of pharmaceutical chemicals. The high-efficiency herbal eye drop contains the following components in parts by weight: 80-100 parts of water, 50-60 parts of polycarbophil AA, 30-40 parts of oxytetracycline, 25-30 parts of tafluprost, 20-25 parts of timclol maleate, 18-23 parts of herba houttuyniae extract, 16-21 parts of flos lonicerae extract, 13-18 parts of semen cassiae extract, 11-16 parts of rhizoma coptidis extract, 9-13 parts of sodium chloride, 6-11 parts of edetate disodium, 6-9 parts of poloxamer, 5-8parts of tyloxapol, 4-8 parts of timclol maleate, 4-6 parts of brinzolamide, 2-5 parts of mannitol, 2-5 parts of citric acid, 2-4 parts of sodium citrate, 1-3 parts of benzene, and 1-3 parts of a preservative. The high-efficiency herbal eye drop solves the problems that a traditional herbal eye drop has poor absorption and a poor effect, and a chemical preparation eye drop hurts eyes.

The present invention relates to a process for preparing sterile ophthalmic suspension of carbonic anhydrase inhibitor. More particularly, the present invention relates to a process for preparing sterile ophthalmic suspension of brinzolamide.

Disclosed herein are safe pharmacologically acceptable and ophthalmologically suitable compositions and methods of their use in treating ophthalmic diseases or related conditions. Disclosed are compositions comprising effective amounts of carbonic anhydrase inhibitor(s) and alpha-2-adrenergic agonist(s) and an effective amount of a penetration enhancement component comprising one or more penetration enhancer compound(s)/molecule(s), e.g., benzalkonium chloride, which detectably or significantly increases the penetration of API(s) of the composition. In aspects, the invention provides compositions comprising a brinzolamide compound in an amount of about 0.1 wt. %-10 wt. % of the composition, a brimonidine compound, e.g., brimonidine tartrate, in an amount of about 0.01 wt. %-0.5 wt. % of the composition, one or more borate-polyol complexes in an amount of about 0.5 wt. %-6 wt. % of the composition, and a penetration enhancement component comprising benzalkonium chloride, in, for example, an amount of about 0.005-0.02 wt. % of the composition.

The invention provides a medicine composition containing an effective dosage of puerarin and an effective dosage of dorzolamide or brinzolamide or prostaglandin, such as latanoprost, tafluprost and the like or/ and an effective dosage of water-retaining agent or wetting agent or antixerophthalmic ingredients, and application in preparation of medicines, including eye-purpose medicines used for preventing or treating intraocular pressure or elevated intraocular pressure, glaucoma, fundi diseases, optic nerve protection, dry eyes or xerophthalmia or dry eye syndromes of the human being or mammals. The medicine disclosed by the invention has a better curative effect or a smaller side effect or better treatment compliance or a better treatment mode.

The present invention relates to a process for the preparation of Brinzolamide, or 2H-thieno[3,2-e]-1, 2-thiazin-6-sulfonamide, 4-(ethyl amino)-3, 4-dihydro-2-(3-methoxypropyl)-, 1,1-dioxide,(4R)- via intermediates 2,3-dihydro-4H-thieno[3,2-e]-1, 2-thiazin-4-ones, 1,1-dioxide. Further objects of the present invention are the intermediates mentioned above and other intermediates of the synthesis.

The present invention relates to an aqueous ophthalmic solution for treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma, the solution comprising at least 0.5 w/v % brinzolamide dissolved in the solution; hydroxy-propyl-β-cyclodextrin; polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer; and water and/or the process for preparation thereof.

The invention provides compound nano eye drops and a preparation method thereof, and belongs to the technical field of eye drops. The compound nano eye drops provided by the invention simultaneously contain two medicines, namely the plinzolamide and the brimonidine tartrate, and the adhesive, the stabilizer and the osmotic pressure regulator are used in a matched manner, so that the complexity and the medication frequency of combined medication can be reduced; the particle size of solid particles in the eye drops is nanoscale, the specific surface area of the medicine is large, the residence time of the medicine in front of the cornea can improve the irritation effect of the large-particle medicine on eyes, and the compliance of a patient is improved. The adhesive increases the specific surface area of the brinzolamide medicine, increases the residence time of the hydrophobic medicine in front of cornea, reduces the loss of the medicine in eyes, reduces systemic side effects caused by loss through nasolacrimal ducts, improves the bioavailability, prolongs the medication cycle of the eye drops through slow release, and improves the antibacterial and anti-inflammatory effects; no preservative is contained, so that secondary injury to eyes of a patient is avoided.

Disclosed herein are safe pharmacologically acceptable and ophthalmologically suitable compositions and methods of their use in treating ophthalmic diseases or related conditions. Disclosed are compositions comprising effective amounts of carbonic anhydrase inhibitor(s) and alpha-2-adrenergic agonist(s) and an effective amount of a penetration enhancement component comprising one or more penetration enhancer compound(s)/molecule(s), e.g., benzalkonium chloride, which detectably or significantly increases the penetration of API(s) of the composition. In aspects, the invention provides compositions comprising a brinzolamide compound in an amount of about 0.1 wt. %-10 wt. % of the composition, a brimonidine compound, e.g., brimonidine tartrate, in an amount of about 0.01 wt. %-0.5 wt. % of the composition, one or more borate-polyol complexes in an amount of about 0.5 wt. %-6 wt. % of the composition, and a penetration enhancement component comprising benzalkonium chloride, in, for example, an amount of about 0.005-0.02 wt. % of the composition.

The invention relates to combination therapies useful in the treatment and/or prevention of cancer.

Disclosed herein are pharmacologically acceptable and ophthalmologically suitable compositions and methods of their use in treating ophthalmic diseases or related conditions. In aspects, the invention provides compositions comprising effective amounts of carbonic anhydrase inhibitor(s) and alpha-2-adrenergic agonist(s). In facets, compositions comprise a penetration enhancer component comprising one or more penetration enhancer compound(s)/molecule(s). In aspects, the invention provides compositions comprising effective amounts of brimonidine compound(s) and brinzolamide compound(s) capable of being administered once or twice daily for the treatment of elevated intraocular pressure, but which provide similar efficacy to a similar or substantially identical reference product requiring administration three times per day. In facets, the invention provides compositions capable of being administered at a frequency resulting in providing a lower total dose of both brinzolamide and brimonidine compound(s) to a recipient, but nonetheless are as or more effective in IOP control as such similar or substantially identical reference products.

A preparation method of a brinzolamide eye drop is disclosed. The method is as follows: dispersing active ingredient brinzolamide in a wetting agent, meanwhile completely swelling a suspending aidingagent at 60 DEG C, placing for two hours, dissolving an osmotic pressure regulator, a metal ion complexing agent and a preservative conditioner completely at 60 DEG C, adding a brinzolamide-containingwetting agent solution to a suspending aiding agent solution under homogeneous stirring conditions, continuing homogenizing stirring for 5min, adding other solutions, continuing homogenizing for 5min, adjusting pH, sterilizing and filling. The prescription of the brinzolamide eye drop is simple, the preparation method has strong industrialized production operationability, after direct micronization treatment of raw material medicines, a sample is prepared, a large number of manpower, material and financial resources can be saved, and the preparation method has the advantages of simple equipment required for the preparation project and easy process parameter control.

Disclosed herein are pharmacologically acceptable and ophthalmologically suitable compositions and methods of their use in treating ophthalmic diseases or related conditions. In aspects, the invention provides compositions comprising effective amounts of carbonic anhydrase inhibitor(s) and alpha-2-adrenergic agonist(s). In facets, compositions comprise a penetration enhancer component comprising one or more penetration enhancer compound(s)/molecule(s). In aspects, the invention provides compositions comprising effective amounts of brimonidine compound(s) and brinzolamide compound(s) capable of being administered once or twice daily for the treatment of elevated intraocular pressure, but which provide similar efficacy to a similar or substantially identical reference product requiring administration three times per day. In facets, the invention provides compositions capable of being administered at a frequency resulting in providing a lower total dose of both brinzolamide and brimonidine compound(s) to a recipient, but nonetheless are as or more effective in IOP control as such similar or substantially identical reference products.